Phospho-SMAD2 (Thr220) Antibody

What is Phospho-SMAD2 (Thr220) Antibody and what does it specifically detect?

Phospho-SMAD2 (Thr220) Antibody is a specialized immunological reagent that specifically detects endogenous levels of SMAD2 protein only when phosphorylated at threonine 220. This antibody recognizes the phosphorylation site with the peptide sequence P-E-T(p)-P-P derived from human SMAD2 . These antibodies are typically produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates, followed by purification through affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies are removed through chromatography using non-phosphopeptide, ensuring high specificity for the phosphorylated form .

How does Phospho-SMAD2 (Thr220) phosphorylation differ from other SMAD2 phosphorylation sites?

SMAD2 contains multiple phosphorylation sites that serve distinct signaling functions. While the C-terminal phosphorylation sites (Ser465/467) are directly phosphorylated by TGF-β receptor kinases and are critical for canonical TGF-β signaling , the Thr220 site is located in the linker region and represents an alternative phosphorylation mechanism. This linker region phosphorylation can be triggered by non-canonical pathways, including lipopolysaccharide (LPS) stimulation via Toll-like Receptor 4 (TLR4) . Research has demonstrated that the threonine 220 and serine cluster (Ser245/250/255) in the SMAD2 linker region can be phosphorylated by various kinases including TAK-1 and MAPKs , representing a distinct regulatory mechanism compared to the C-terminal phosphorylation.

What experimental techniques are compatible with Phospho-SMAD2 (Thr220) Antibody?

Based on manufacturer specifications, Phospho-SMAD2 (Thr220) Antibody is validated for multiple experimental applications:

HeLa cells are commonly suggested as a positive control for Western blot applications, particularly when treated with PMA or other stimulants that induce SMAD2 phosphorylation .

How is Phospho-SMAD2 (Thr220) involved in TLR4-mediated signaling pathways?

Research has revealed that LPS stimulation of TLR4 can induce phosphorylation of SMAD2 at Thr220, representing a novel signaling mechanism. In vascular smooth muscle cells (VSMCs), LPS (100 ng/mL) treatment stimulated the phosphorylation of the SMAD2 Thr220 residue to 1.8-fold (p < 0.05) at 120 minutes post-treatment . This phosphorylation involves MyD88-dependent pathways and activation of TAK-1 (TGF-β activated kinase-1) .

The signaling cascade appears to involve:

• LPS binding to TLR4

• Activation of MyD88-dependent pathways

• Recruitment of IRAK1/4 and TRAF6

• Activation of TAK-1

• Subsequent phosphorylation of SMAD2 at Thr220

This pathway represents a significant cross-talk between inflammatory (TLR4) and fibrotic (SMAD) signaling pathways that may have implications for atherosclerosis and other inflammatory vascular diseases .

What kinases are responsible for SMAD2 Thr220 phosphorylation under different stimulation conditions?

Multiple upstream kinases can phosphorylate SMAD2 at Thr220 depending on the stimulation conditions:

• TAK-1: In LPS-stimulated vascular smooth muscle cells, TAK-1 appears to be a critical upstream kinase. Inhibition of TAK-1 with the inhibitor NG25 dose-dependently blocked LPS-induced Thr220 phosphorylation .

• MAP Kinases: Specific MAP kinases also contribute to Thr220 phosphorylation:

  • MEK1/2-ERK pathway: The MEK1/2 inhibitor UO126 completely inhibited LPS-mediated SMAD2 Thr220 phosphorylation

  • JNK pathway: The JNK inhibitor SP600125 completely inhibited LPS-mediated SMAD2 Thr220 phosphorylation

  • p38 pathway: Surprisingly, the p38 inhibitor SB202190 had no effect on Thr220 phosphorylation, while affecting other linker phosphorylation sites

• Nemo-like kinase (NLK): Research indicates that NLK may also phosphorylate the SMAD2/3 linker region, potentially including Thr220, although the specific relationship to this site requires further investigation .

How does the phosphorylation kinetics of SMAD2 Thr220 compare with other linker region phosphorylation sites?

LPS treatment of vascular smooth muscle cells showed distinct phosphorylation kinetics between Thr220 and the Ser245/250/255 cluster in the SMAD2 linker region:

• Thr220 phosphorylation: Peaked at 120 minutes post-LPS treatment (1.8-fold increase, p < 0.05)

• Ser245/250/255 phosphorylation: More rapid onset, with 1.5-fold increase within 15 minutes, 2.2-fold (p < 0.01) at 60 minutes, and peak stimulation of 2.5-fold (p < 0.01) at 120 minutes

This differential phosphorylation pattern suggests potentially distinct regulatory mechanisms and functions for different phosphorylation sites within the linker region, with potential implications for downstream gene regulation.

What are the optimal conditions for detecting SMAD2 Thr220 phosphorylation in cellular assays?

Based on the research findings, the following experimental conditions have proven effective for detecting SMAD2 Thr220 phosphorylation:

• LPS stimulation: 100 ng/mL concentration for 120 minutes showed optimal phosphorylation of Thr220 in vascular smooth muscle cells

• Western blotting: Use appropriate lysis buffers containing phosphatase inhibitors to preserve phosphorylation status

• Cell types: HeLa cells show reliable phosphorylation and are often used as positive controls

• Alternative stimulation: TGF-β treatment can also induce Thr220 phosphorylation (2.2-fold, p < 0.01) and can serve as a positive control

• Loading controls: Total SMAD2 antibody should be used in parallel to normalize phosphorylation levels

For dose-response studies, LPS concentrations between 1-100 ng/mL show a dose-dependent increase in phosphorylation, with 100 ng/mL producing maximum response (2.6-fold, p < 0.05) .

What are the critical storage and handling requirements for maintaining Phospho-SMAD2 (Thr220) Antibody activity?

To maintain optimal antibody performance, follow these storage and handling guidelines:

The antibodies are typically supplied in stabilizing buffers such as:

• 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide

• Phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol

For optimal results, avoid repeated freeze-thaw cycles by aliquoting the antibody into smaller volumes before freezing . Most commercially available antibodies have an expiration period of 12 months from the date of shipment when stored properly .

How can specificity of Phospho-SMAD2 (Thr220) Antibody be validated in experimental settings?

To validate the specificity of Phospho-SMAD2 (Thr220) Antibody in your experiments, consider the following approaches:

• Phosphopeptide competition assay: Perform dot blot analysis using 50ng of phospho-peptide versus non-phospho-peptide. A specific antibody will only bind to the phosphorylated form .

• Phosphatase treatment controls: Treat half of your sample with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show decreased or abolished signal in the phosphatase-treated sample.

• Kinase inhibition: Use specific inhibitors of upstream kinases (like TAK-1 inhibitor NG25, MEK inhibitor UO126, or JNK inhibitor SP600125) which should reduce or eliminate phosphorylation at Thr220 .

• Stimulation time course: Stimulate cells with LPS or TGF-β and analyze phosphorylation at multiple time points (15, 60, 120 minutes) to confirm the expected time-dependent phosphorylation pattern .

• Genetic approaches: Use cells with SMAD2 knockdown or expressing a T220A mutant form of SMAD2 as negative controls.

How does LPS-induced SMAD2 Thr220 phosphorylation contribute to atherosclerosis pathophysiology?

LPS-induced phosphorylation of SMAD2 at Thr220 represents a significant molecular mechanism linking bacterial infections to atherosclerosis progression. Research indicates that:

• Atherosclerosis begins with the retention of low-density lipoproteins to modified proteoglycans with hyperelongated glycosaminoglycan (GAG) chains in the vessel wall .

• Bacterial infections produce endotoxins like LPS that exacerbate atherosclerosis by generating heightened inflammation and potentially by modifying proteoglycans .

• LPS stimulates phosphorylation of SMAD2 at Thr220 in vascular smooth muscle cells through TLR4 signaling pathways .

• This phosphorylation appears to regulate GAG chain elongation, potentially enhancing the binding and retention of LDL particles in the vessel wall .

• The signaling pathway involves MyD88-dependent activation of TAK-1 and subsequent activation of MAP kinases (particularly ERK and JNK), which then phosphorylate SMAD2 at Thr220 .

This non-canonical activation of SMAD2 represents a novel mechanism by which bacterial infections may accelerate atherosclerosis, independent of the classical inflammatory response associated with TLR4 activation.

What is the relationship between Thr220 phosphorylation and other SMAD2 phosphorylation events in signal integration?

SMAD2 integrates multiple signals through distinct phosphorylation events that together determine the cellular response:

• C-terminal phosphorylation (Ser465/467): Represents the canonical TGF-β signaling pathway where direct phosphorylation by TGF-β receptor I kinase activates SMAD2, leading to complex formation with SMAD4 and nuclear translocation .

• Linker region phosphorylation (Thr220): Can be induced by both TGF-β (2.2-fold) and LPS (1.8-fold), suggesting this site integrates signals from multiple pathways .

• Serine cluster phosphorylation (Ser245/250/255): Shows different kinetics and may respond to different upstream kinases compared to Thr220, with p38 inhibition affecting Ser245/250/255 but not Thr220 phosphorylation .

These distinct phosphorylation events create a "SMAD code" that allows for nuanced regulation of SMAD2 function. The phosphorylation of Thr220 appears to be particularly important in cross-talk between inflammatory (TLR4) and fibrotic (TGF-β) signaling pathways, potentially representing a mechanism by which inflammation can modulate TGF-β responses.

What experimental considerations should be taken when studying temporal dynamics of SMAD2 phosphorylation at multiple sites?

When investigating the complex temporal dynamics of SMAD2 phosphorylation at multiple sites, researchers should consider:

• Time course design: Include both early (15 min) and late (120 min) time points to capture the differential kinetics of phosphorylation at different sites. Research shows that Ser245/250/255 phosphorylation occurs more rapidly (within 15 min) than Thr220 phosphorylation (peaks at 120 min) .

• Site-specific antibodies: Use highly specific antibodies that recognize distinct phosphorylation sites (Thr220 vs. Ser465/467 vs. Ser245/250/255) to track the phosphorylation status of each site independently .

• Upstream kinase inhibitors: Apply specific inhibitors of TAK-1, ERK, JNK, and p38 to dissect the contribution of each kinase to the phosphorylation of different sites. For example, p38 inhibition affects Ser245/250/255 but not Thr220 phosphorylation .

• Quantitative analysis: Use quantitative Western blotting with appropriate normalization to total SMAD2 to accurately measure phosphorylation levels at each site.

• Functional correlation: Correlate the temporal patterns of phosphorylation with downstream functional outcomes such as target gene expression or cellular phenotypes to understand the biological significance of each phosphorylation event.

• Mathematical modeling: Consider developing computational models that integrate the dynamics of multiple phosphorylation events to predict how cells interpret complex signaling inputs.

By carefully addressing these considerations, researchers can gain insights into how cells integrate multiple signals through the differential phosphorylation of SMAD2, potentially leading to the development of more targeted therapeutic approaches for diseases involving dysregulated SMAD2 signaling.

What are the emerging roles of Nemo-like kinase (NLK) in regulating SMAD2 linker phosphorylation?

Recent research has highlighted the potential role of Nemo-like kinase (NLK) in regulating SMAD2/3 linker phosphorylation, adding another layer of complexity to SMAD regulation:

• NLK has been identified as a kinase that can phosphorylate the linker region of SMAD2/3, potentially including sites like Thr220, though specific relationships to individual phosphorylation sites require further investigation .

• The interaction between NLK and SMAD2/3 has been studied using mass spectrometry approaches to identify phosphorylation sites, involving purified GST-tagged SMAD2 proteins incubated with immunoprecipitated NLK .

• These interactions may represent alternative pathways for regulating SMAD2 function independent of the canonical TGF-β pathway, potentially integrating with other cellular signaling networks.

• Understanding the exact mechanisms by which NLK regulates SMAD2 linker phosphorylation could provide new insights into diseases where TGF-β signaling is dysregulated.

Future research should focus on determining the specific sites phosphorylated by NLK, the stimuli that activate this pathway, and the functional consequences of NLK-mediated phosphorylation on SMAD2 activity.

How can phospho-specific antibodies like anti-phospho-SMAD2 (Thr220) advance our understanding of signaling network integration?

Phospho-specific antibodies such as anti-phospho-SMAD2 (Thr220) serve as critical tools for unraveling complex signaling networks:

• Pathway cross-talk detection: These antibodies have revealed unexpected connections between inflammatory (TLR4) and fibrotic (SMAD) signaling pathways that would not be apparent from studying either pathway in isolation .

• Temporal resolution: By using phospho-specific antibodies in time-course experiments, researchers can track the dynamic phosphorylation of specific residues, revealing how signals propagate through cellular networks with precise timing .

• Spatial mapping: Combined with immunofluorescence techniques, these antibodies allow researchers to visualize where in the cell specific phosphorylation events occur, providing insights into compartmentalized signaling .

• Quantitative biology: When used in combination with quantitative techniques like Western blotting or mass spectrometry, these antibodies enable precise measurement of phosphorylation levels, facilitating mathematical modeling of signaling networks .

Future applications may include:

• Development of multiplexed detection systems to simultaneously monitor multiple phosphorylation sites

• Integration with single-cell analysis techniques to understand cell-to-cell variability in signaling responses

• Application to patient samples to identify dysregulated signaling in disease states

• Use in high-throughput screening to identify compounds that selectively modulate specific phosphorylation events

By advancing these approaches, researchers can develop a more comprehensive understanding of how cells integrate diverse signals to produce appropriate biological responses.